Resmed (RMD) Cost of Revenue (2009 - 2026)

Resmed (RMD) has 18 years of Cost of Revenue data on file, last reported at $532.6 million in Q1 2026.

• Quarterly Cost of Revenue rose 1.38% year-over-year to $532.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.1 billion (up 1.64% YoY) and the FY2025 annual result came in at $2.1 billion, up 3.12% from the prior year.
• Cost of Revenue slipped to $532.6 million in Q1 2026, from $536.3 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $536.3 million in Q4 2025 to a low of $362.3 million in Q1 2022.
• A 5-year average of $483.3 million and a median of $504.2 million in 2024 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2023 — Cost of Revenue soared 37.76% — and 2024, when it fell 5.94%.
• Tracing RMD's Cost of Revenue over 5 years: stood at $446.7 million in 2022, then rose by 13.63% to $507.6 million in 2023, then rose by 4.57% to $530.8 million in 2024, then advanced by 1.03% to $536.3 million in 2025, then decreased by 0.69% to $532.6 million in 2026.
• The last three Cost of Revenue figures came in at $532.6 million (Q1 2026), $536.3 million (Q4 2025), and $506.9 million (Q3 2025), per Business Quant data.